<DOC>
	<DOCNO>NCT02682680</DOCNO>
	<brief_summary>A 24-week , randomize , open-label study investigate efficacy , safety tolerability colesevelam 3.75 g daily compare ezetimibe 10 mg daily , add-on baseline statin therapy patient type 2 diabetes mellitus ( T2DM ) target glycated hemoglobin ( HbA1c ) ( &gt; 7.0 % ) low-density lipoprotein ( LDL ) cholesterol ( &gt; 2.0 mmol/L ) .</brief_summary>
	<brief_title>Randomized Trial Comparing Colesevelam vs. Ezetimibe</brief_title>
	<detailed_description>This study enroll 440 adult patient T2DM target HbA1c LDL cholesterol . Patients baseline statin therapy randomly assign 1:1 ratio colesevelam 3.75 g daily 24 week , ezetimibe 10 mg daily 24 week . If patient statin intolerance , may fibrate and/or niacin , lipid lower therapy . The primary efficacy objectives 1. demonstrate colesevelam 3.75 g daily non-inferior ezetimibe 10 mg daily add-on statin therapy patient achieve composite target HbA1c ( ≤ 7.0 % ) LDL cholesterol ( ≤ 2.0 mmol/L ) week 24 , 2. compare proportion patient achieve composite target HbA1c ( ≤ 7.0 % ) LDL cholesterol ( ≤ 2.0 mmol/L ) week 24 . This study also assess primary composite outcome sub-group patient sodium/glucose cotransporter 2 inhibitor ( SGLT2i ) therapy .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Colesevelam Hydrochloride</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>1 . Diagnosis type 2 diabetes &gt; 6 month 2 . HbA1c level 7.1 10.0 % ( inclusive ) within three month study enrollment 3 . LDL cholesterol &gt; 2.0 mmol/L within three month study enrollment 4 . Receiving stable dose statin minimum three month , investigator plan change 24week trial period . If patient document statin intolerance , may fibrate and/or niacin , lipid lower therapy 5 . Stable diabetes medication previous three month ( apart adjustment insulin dose ) 6 . Informed consent 1 . Use second lipid lower therapy statin within three month study enrolment , unless fibrate and/or niacin patient statin intolerance 2 . Triglycerides ≥ 5.0 mmol/L incalculable LDL cholesterol 3 . Significant liver enzyme CK elevation define CK ALT ≥ 3x upper limit normal ( ULN ) 4 . Thyroid stimulate hormone ( TSH ) ≥ 5.0 milliinternational unit per litre ( mIU/L ) actively use thyroid hormone replacement therapy 5 . Pregnant breast feed plan become pregnant breast feed study 6 . Chronic kidney disease ( CKD ) stage ≥4 estimate glomerular filtration rate ( eGFR ) &lt; 30 ml/min/1.73 msquared 7 . Severe gastroparesis history significant bowel resection 8 . Current use Investigational Product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>diabetes</keyword>
	<keyword>hyperlipidaemia</keyword>
	<keyword>colesevelam</keyword>
	<keyword>ezetimibe</keyword>
	<keyword>LDL cholesterol</keyword>
	<keyword>glycated hemoglobin</keyword>
</DOC>